Translational Research Program
Guidelines & Instructions

Effective dates:
August 21, 2023 – June 30, 2024
Table of Contents

Application Compliance ................................................................................................................... 2
About The Leukemia & Lymphoma Society, Inc ........................................................................... 3
Program Description ....................................................................................................................... 3
Who Can Apply ................................................................................................................................. 4
Review Process & Applicant Notification .......................................................................................... 5
Key Dates ........................................................................................................................................... 5
Review Criteria ................................................................................................................................. 6
Request Proposal Information ........................................................................................................... 7
General Application Instructions ....................................................................................................... 10
Detailed Letter of Intent Phase Instructions ..................................................................................... 12
Detailed Full Application Phase Instructions ................................................................................... 14
Application Compliance

- It is highly recommended to access the LLS Research Portal at https://lls.fluxx.io and begin the application process well in advance of any deadlines. In addition, each stage of the application process (letter of intent/full application) should be completed well before the deadline.

- Note that early-stage, pre-translational, or discovery work is not the best fit for TRP and will not be competitive. These types of applications are best suited for our Discovery Grant Program (formerly known as our Blood Cancer Discoveries Grant program) and potential Principal Investigators are encouraged to apply to that program.

- All components of the application must be present in the order indicated in these guidelines.

- Character limits include spaces. Character and other length limits are strictly enforced on the web form and the uploaded project description template. Font must be black Arial 11 pt. including figure legends, which should be text boxes separate from the figure itself. If character limits and font restrictions are not adhered to, or the preset margins are altered, the application may be administratively disqualified.

- Line spacing is preset in the Word document. Do not change the setting. Pasting text from another document into the template may result in a change in the line spacing. Check the line spacing in the template before pasting, and if there is a change after pasting, return the line spacing to the original setting. Any modifications in line spacing, particularly if the change allows for more text to fit into the page, may result in administrative disqualification of your application.

- Do not attach documents to the application that are not specifically called for. The application may be administratively disqualified if this rule is violated.

- The PI and/or Co-PI may apply to more than one grant program during an application cycle if the aims do not substantially overlap with the aims of any other application across all programs. You may not be on a different project within the same grant program.

- The Project/Core Leaders, Collaborators or Key Personnel may be on different projects or programs provided the aims differ.

- All such duplicate grant proposal submissions with substantially overlapping aims are subject to administrative disqualification, and such proposals will not be reviewed further or considered for funding. Contact researchprograms@lls.org with any questions about this policy or to discuss with LLS scientific staff any questions concerning potential overlap.

- Completion of several steps in the process initiates emails sent from the LLS Research Portal. LLS staff may also send emails during the application process. Spam filters should be monitored for these emails. Contact researchprograms@lls.org if expected emails are not received by the times indicated in these guidelines or if you have any questions not clarified in this document.
About The Leukemia & Lymphoma Society, Inc.

The Leukemia & Lymphoma Society, Inc. (LLS) is a national voluntary health agency dedicated to the conquest of hematologic malignancies and relevant premalignant conditions. LLS supports research, patient aid, community service programs, advocacy, and public and professional education.

Program Description

The Translational Research Program (TRP) was formed to enhance the transfer of basic research findings to clinical usefulness.

Applications are sought that propose novel approaches to the prevention, diagnosis, or treatment of hematological malignancies and related pre-malignant conditions. Proposals should be based on molecular, cellular, or integrated systems findings and be conceptually innovative. The application should have a clear plan for the eventual clinical translation of the studies proposed and the results expected. This feature will be an important consideration of the review process.

Applicants must submit a proposed budget with justification. The budget submitted should reflect the actual needs of the project but cannot exceed $250,000 USD per year / $750,000 USD total for the three (3) years of the grant. This budget ceiling includes all costs associated with the grant including indirect costs (often referred to as Institutional Overhead), which will be capped at 10% of the total award. Indirect costs are optional and can be applied to direct costs instead. Please note that LLS does not follow NIH guidelines for budgets.

<table>
<thead>
<tr>
<th>Duration</th>
<th>Maximum Per Year</th>
<th>Maximum Award Value for the three years of the grant</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 years</td>
<td>$250,000</td>
<td>$750,000</td>
</tr>
</tbody>
</table>

In total, no more than forty percent (40%) of the direct costs may be requested for the salary and fringe benefit expenses of professional staff with a post-graduate degree (i.e., MD, PhD, DVM) regardless of function or role. This restriction does not apply to technical staff (lab assistants, nurses, etc.).

The TRP award amount you are given will reflect the amount you request in the budget section of your application. Any requests to increase funding must be in writing to LLS and are subject to the availability of funds.
Who Can Apply

Citizenship
The program welcomes applications worldwide from appropriate academic institutions and investigators of any nationality.

Degree
Applicants must hold a PhD, MD, DVM, or equivalent degree.

Leadership and Staffing

The Principal Investigator (PI):
- MUST be a person (companies or institutions are not eligible)
- MUST be an independent investigator, defined as a scientist who has dedicated laboratory space, directly hires, and supervises laboratory personnel (technicians, graduate students, postdocs, and staff scientists), and makes all decisions concerning research activities and use of the grant funds
- MUST be an established investigator, defined as a researcher with more than 3 years in an independent faculty appointment
- May only submit one application per application cycle per grant program provided the aims differ
- CAN serve as a Collaborator on other applications provided the aims differ
- If the applicant can demonstrate a significant track record in malignant hematology and/or blood cancer research, a Co-PI may strengthen the proposal but is not required
- If the applicant has scientific achievements and significant expertise in another scientific area and no track record in blood cancer research, he or she MUST have a Co-Principal Investigator who has the required significant track record in hematology and/or blood cancer research

Not eligible to apply for a grant in this program:
- Predoctoral scientists or postdoctoral fellow

A Co-Principal Investigator (Co-PI):
- MUST be a person (companies or institutions are not eligible)
- MUST be an independent investigator with an independent appointment
- If the PI has the necessary track record in blood cancer research, a Co-PI may strengthen the proposal but is not required
- If the PI has no expertise or proven track record in any of the blood cancers, an expert Co-PI is REQUIRED
- May only submit one application per application cycle per grant program provided the aims differ
- CAN serve as a Collaborator on other applications provided the aims differ
- MUST be designated at the LOI phase detailing the nature and extent of the scientific interaction
- At least one research aim of the proposal fully depends on their expertise, typically performed in their laboratory and/or facility
Scientific Staff/Collaborators/Other Key Personnel
- MUST be a person (companies or institutions are not eligible)
- May strengthen the work proposed but is not required
- May provide expert insight, guidance, or feedback on research progress
- May be included on different projects or programs provided the aims differ

The Application will require one Principal Investigator who is responsible for the preparation and submission of the proposal including budget, the conduct of the research programs, and adherence with all stipulations made by LLS in this document, the Policies & Procedures document, and in the Funding Agreement, if funded.

Relevance
The proposed research should be clinically directed or clinically translatable in hematologic malignancies that is intended to develop innovative approaches to treatment, diagnosis, or prevention.

Review Process & Applicant Notification

The deadline to submit all Letters of Intent (LOI) is October 20, 2023, at 3 PM ET. Letters of Intent for the TRP RFP topics will be reviewed after the LOI deadline. Applicants will be notified via an automated email whether they are invited to submit a full application or whether their LOI was declined. We will only be inviting full applications that will be competitive. If the applicant is invited to submit a full application, immediate access to the full application phase is enabled in the LLS Research Portal. If you have not received an email regarding your LOI approval by November 17, 2023, contact researchprograms@lls.org.

The deadline to submit all full applications is January 19, 2024, at 3 PM ET. Full applications will only be accepted via the LLS Research Portal.

Key Dates

<table>
<thead>
<tr>
<th>Phase</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Call For Proposals</td>
<td>August 21, 2023</td>
</tr>
<tr>
<td>Letter of Intent due</td>
<td>October 20, 2023</td>
</tr>
<tr>
<td>Full Application due</td>
<td>January 19, 2024, 3:00 PM ET</td>
</tr>
<tr>
<td>Panel Review Meeting</td>
<td>March 2024</td>
</tr>
<tr>
<td>Award Notification</td>
<td>May 2024</td>
</tr>
<tr>
<td>Award Start Date</td>
<td>July 1, 2024</td>
</tr>
</tbody>
</table>

*LLS’s non-negotiable funding agreement terms & conditions are available on www.lls.org.

All submission deadlines will be enforced. Please note that all times are Eastern Time (ET). If any date falls on a weekend or US holiday, the deadline becomes the next business day.
It is highly recommended that submissions are done prior to the deadlines. Internet traffic may be slow near the deadlines, which may result in difficulties in submissions. In addition, LLS’s response time to questions may be delayed by the high volume received near the deadlines. Therefore, it is imperative that any submissions or questions be posed to LLS well ahead of any deadlines.

Review Criteria

An application will be judged on these criteria, again noting the preference for later stage asset development:

- The probability of an advance in prevention, diagnosis, or treatment in the near-term.
- The conceptual basis upon which the proposal rests.
- A well-planned strategy to accomplish the aims presented.
- The novelty of the concept and strategy.
- Thoughtful and clear presentation.
- The overall plan for bringing the research findings to clinical application.
- Experience, background, and qualifications of investigators.
- Adequacy of resources and environment (facilities, access to patient samples if needed, data management and data analysis, etc.).
- Adequacy of provisions for protection of human subjects.
- If applicable, a patient involvement plan to address the needs and input of patients
- **DEI**: The applicant demonstrates understanding of any health disparities associated with the indication; and the applicant presents an appropriate rationale and plan for the proposed trial study population based on current knowledge of the groups at risk for the target indication, including underserved populations. The rationale and plan for the study population align with the objectives of the trial.

Full Applications will be reviewed after the January 19, 2024, submission deadline by the TRP Subcommittee of the Medical & Scientific Affairs Committee. If an application does not meet the program goals, scope, or guidelines, it may be administratively disqualified. Applications are assigned an initial score by the primary and secondary reviewers. Only applications that fall above a scoring level determined by the committee chair will be discussed in detail for final ranking by the entire committee.

TRP applications will be rank ordered based on their Overall Priority Score (1-9; which reflects the average of all the reviewers’ priority scores).

Once ranked, priority scores and funding recommendations of the TRP Subcommittee will be presented to the Medical & Scientific Affairs Committee and LLS’s National Board of Directors for final determination of awardees. The Board of Directors will determine the number of awards funded based on scientific merit and the budget approved.

Any applicant selected for funding will be notified by the date indicated in the Key Dates section. Please do not call or email LLS to determine whether the application has been received, when it will be reviewed, or the results of the review. Please check the LLS Research Portal for the status of your application. All priority scores are confidential in that they are available to LLS’s Medical & Scientific Affairs Committee, its Research Subcommittee, LLS’s National Board of Directors, and administrative personnel only. **Feedback will only be provided for applications discussed by the full review committee.**

LLS will continue to pursue proposals in several specific research areas that it considers...
“high unmet need.”

Request For Proposal Information

If your proposed research falls within a topic listed, please choose “Yes” in the LLS Research Portal. If it does not, choose “No.” Choosing “No” for all topics does not disqualify your application from review. The LLS seeks proposals responsive to the requests for proposals but will also consider other exceptional proposals with the near-term potential for clinical translation. Applicants with research proposals that are responsive to the RFP should indicate this on the title page of their Full Application.

Special Opportunity for Follicular Lymphoma, Australian, and Canadian Grants through the LLS Translational Research Program (TRP):

1) The Leukemia & Lymphoma Society – The Follicular Lymphoma Foundation Translation Research Program. LLS is partnering with The Follicular Lymphoma Foundation (FLF) to advance our common mission to find cures for follicular lymphoma and improve the quality of life of patients and their families. LLS and FLF will jointly fund up to three meritorious TRP applications focused on Follicular Lymphoma with an emphasis on late stage pre-clinical or clinical investigations aimed toward driving cures. Applications must be submitted to the LLS TRP program and will be evaluated within the general pool of TRP applications. Applications will be jointly reviewed by LLS and FLF for co-funding decisions. LLS will administer the grant program. Details to be found in “Cure FL Appendix” at the end of the Guidelines and Instructions.

2) Snowdome Foundation – Leukaemia Foundation Translational Research Program. The Snowdome Foundation and Leukaemia Foundation are Australian-based not-for-profit organizations with whom LLS is partnering to enhance our common goal to accelerate cures and better treatments for blood cancer patients. LLS, Snowdome Foundation and Leukaemia Foundation will jointly fund up to one meritorious TRP application focused on blood cancer research from investigators working in Australia, Australian investigators working in other countries, or to Australian and non-Australian researchers jointly applying as co-PIs. Applications must be submitted to the LLS TRP program and will be evaluated within the general pool of TRP applications. In addition, applications will be jointly reviewed by all three foundations to ensure they meet the funding objectives of the organizations, and scientific progress of each awarded TRP will be evaluated by the organizations on an annual basis. LLS will administer the grant program.

3) The Leukemia & Lymphoma Society–The Leukemia & Lymphoma Society of Canada Translational Research Program. LLS is partnering with The Leukemia & Lymphoma Society of Canada (LLSC) to advance our common mission to find cures for blood cancers and improve the quality of life of patients and their families. LLS and LLSC will jointly fund up to three meritorious TRP applications focused on blood cancer research from investigators...
working in Canada. Applications must be submitted to the LLS TRP program and will be evaluated within the general pool of TRP applications. Applications will be jointly reviewed by LLS and LLSC and scientific progress of each awarded TRP will be evaluated by both organizations on an annual basis. LLS will administer the grant program.

If you have selected eligibility for Snowdome/Leukaemia Foundations, Canada, or Follicular Lymphoma Foundation co-funds, please ensure you select at least one topic of interest as outlined below. Co-fund opportunities are included with the entire applicant pool and will undergo the same review process as all other applications received. The co-fund opportunities solely reflect the source of funding.

**Special Topics of Interest:**

LLS is calling applicant’s attention to one specialized focused subsection of the TRP program. This program will receive preferential funding as a mechanism to drive for further clinical development of novel agents to improve outcomes for patients.

**Mantle Cell Lymphoma**

LLS invites innovative and ambitious proposals that can lead to better treatments and cures for MCL. In particular, the goals of MCL are to better understand and develop therapeutic approaches for relapsed MCL. However, novel work focused on early disease intervention or improved risk stratification is of interest. LLS calls for the submission of creative proposals with the potential for high impact in MCL. Applications should address both transformative issues in MCL biology and promising new directions in MCL therapy.

**Key Topics of Interest:**

- Understanding of the MCL tumor microenvironment and the properties of lymphoma cells responsible for disease relapse
- Identifying the best treatment combinations based on solid preclinical rationale and data
- Understanding and developing novel immunotherapies for MCL that have the potential to cure cancer
- Identification and validation of novel targets in relapsed disease
- Developing treatment approaches that replace cytotoxics with targeted therapies or immunotherapies that retain efficacy while reducing toxicity
- Understanding the basis of resistance to existing and newly emerging therapies
- Developing novel therapeutics, especially to targets that are unique to MCL and have previously been difficult to drug (e.g., transcription factors)
- Developing additional, accurate animal models of the disease for critical testing of drugs
- Developing predictive biomarkers of disease that can be used for early detection, prediction of treatment response, and to identify patients most likely to respond well to different treatments

**General Topics of Particular Interest:**

1. **Personalized medicine approach for cancer treatment.** Advances in cancer care have significantly improved lives of patients with hematologic diseases such as CLL, CML, Hodgkin Lymphomas, MM, and ALL. LLS believes that, with time, cures can be achieved for certain diseases or subtypes of diseases. Therefore, LLS will continue to support research that may revolutionize cancer care for any hematologic disease including the use of state-of-the-art technologies for molecular profiling, novel target identification, prognostic/predictive biomarkers that can be associated with patient selection and development of liquid biopsy technology.
2. Development of novel therapies and/or novel therapeutic strategies including those that target mutational and epigenetic events both in the tumor cells and within the microenvironment. Such therapies can be applicable to any hematologic malignancies, but emphasis is warranted in the following areas:

   a) Aggressive subtypes of Non-Hodgkin Lymphoma including but not limited to DLBCL, tFL, MCL, PTCL, and ALCL
   b) Indolent lymphoma, including but not limited to: CLL, FL, WM (therapies with the potential to provide significant extension of lives of patients or total disease control in defined subtypes)
   c) Myeloid disorders including MPN/MDS/AML as well as lymphoid disorders such as ALL
   d) Multiple Myeloma and pre-emergent conditions
   e) LLS is especially interested in novel immunotherapy approaches and understanding novel immune synapses relevant to blood cancers.

3. Improvements in the safety and efficacy of stem cell transplantation

4. Long-term outcome assessment following therapies

5. Pediatric research. LLS recognizes that new, precision medicine and immunotherapies are needed to improve outcomes for pediatric blood cancers. The goal is to develop curative therapies that have reduced long-term complications compared to current cytotoxic therapies. Research may focus on pediatric leukemias, lymphomas, as well as other pediatric blood cancers such as Langerhan’s Cell Histiocytosis. We encourage research applications attempting to justify and explore novel therapies for pediatric blood cancers, especially those that uniquely target mutations found in pediatric cancers.

6. Cancer Cell/Microenvironment: Progress in understanding neoplastic stem cell growth and differentiation as well as cancer cell/microenvironment interactions especially with translation to novel therapies.
General Application Instructions

All submissions must use the LLS Research Portal at https://lls.fluxx.io. It is recommended that you familiarize yourself with this portal well in advance of any deadlines.

Registration
Both the applicant and institution must be registered in the LLS Research Portal. If you have applied to LLS in the past, you do not need to create a new registration. Simply log in with your username and password. If you forgot your password, click the “reset or create password” link and enter your email address. The system will send your username and a link to update your password. Once updated, you can begin the LOI. If you are a first-time user to the LLS Research Portal, please complete the intake form located at this link: Account Creation Request so an account can be created for you. Only LLS staff members have administrative permission to create new accounts.

Institutional Designation
Applicants should create their profile from the standpoint of where they will perform the research described in the application. The applicant must indicate the name of the institution as well as the name of the signing officials for that institution.

If your institution is not displayed as an option under this field of the application, you may contact researchprograms@lls.org to have it registered in the system. Please provide the official’s full name and email address.

Data Entry
Both the LOI and the full application may be accessed and changed multiple times as needed prior to the submission deadline. However, neither the LOI nor the full application can be changed once the respective deadlines have passed or the final application has been submitted. Moreover, some fields may not be modified in the full application following submission of the LOI.

Forms and Format
Applicants will provide information on the LLS Research Portal and a downloadable template at the LOI and full application phases. All information must be typed in English using commonly accepted grammar and punctuation. Some information will be captured when applicants populate fields on the LLS Research Portal. Fields in bold are required. Character limits include spaces. Character and other length limits are strictly enforced on the web form and the uploaded project description template.

Font must be black Arial 11 pt. including figure legends, which should be text boxes separate from the figure itself. If character limits, font restrictions, margins and/or page limitations are not adhered to, the application may be administratively disqualified.

Contacting LLS
Questions that are not clarified in this document or the LLS Research Portal should be addressed to researchprograms@lls.org.
**Beginning an application**
The application will be completed in two phases: Letter of Intent and Full Application. Below are step-by-step instructions for applying:

1) Read the Guidelines & Instructions in full and familiarize yourself with the [LLS Research Portal](#).

2) Log into the LLS Research Portal, and under “Information” in the left navigation bar, select Translational Research Program. Click “Apply to TRP!” to begin the application process (well ahead of the deadline).

3) Click “Edit” and follow the instructions for each web form field. Bold font indicates required information.
   - Character limits include spaces. Character and other length limits are strictly enforced on the web form and the uploaded project description template. If character limits are not adhered to, the application may be disqualified.
   - You may save your work and return to it at any time by clicking “Save.” Clicking “Submit” will lock your application and prevent further modification at that stage. Contact researchprograms@lls.org if you submit in error (must be before the deadline).

4) Once your LOI is submitted, you will receive an automated confirmation and email within two business days from the [LLS Research Portal](#). Consider that these emails may end up in your spam filter.

5) If your LOI is selected, you will have access to the full application. Click on your request, found in New or Pending, to continue with your application.

6) Please carefully follow the instructions on the [LLS Research Portal](#) and this document. Full applications require completion of both the web form and the application template, which should be downloaded from the Project or Supporting Documentation section of the LLS Research Portal. **Failure to follow all application instructions may result in administrative disqualification of your application.**

7) Submit your full application to the [LLS Research Portal](#) prior to the full application deadline. **We strongly recommend submitting well before the deadline, as site traffic on the day of and days leading up to the deadline will be heavy.** Contact researchprograms@lls.org with any questions about the application phases that are not addressed in the LLS Research Portal, the FAQ, or this document.

8) To create a fair process to all applicants, these Guidelines & Instructions and information on the [LLS Research Portal](#) must be followed. **Do not ask for exceptions to these policies, including but not limited to exceptions to deadlines or making corrections to your document past the deadline.**

   Carefully check every page of your application prior to submission. You are ultimately responsible for this submission, even if someone else submits your final application.

   **Should you have any technical difficulties with the [LLS Research Portal](#), please contact researchprogram@lls.org.**
Detailed Letter of Intent Phase Instructions

Each applicant must submit the LOI by **October 20, 2023, at 3:00pm ET** via the LLS Research Portal (https://lls.fluxx.io). The applicant should carefully craft the information requested in the LOI as this information is automatically populated into the full application and is subject to the “Changes” clause listed below. There are two main aspects to the Letter of Intent Phase: all Fluxx webform fields and the “Previous Studies/Preliminary Data” (1 page maximum) downloadable template for completion.

The LOI for the TRP RFP topics will be reviewed after the deadline. If the LOI is approved, the applicant will be notified by an automated email from the LLS Research Portal stating that they may proceed to the full application phase. Applicants may also check the status of their LOI on the LLS Research Portal.

Organization Information

(If the institution or officials are not listed, please contact researchprograms@lls.org with the name and email address for the official you need added)

**Institution:** Indicate the name of the institution where the research will be performed.

**Principal Investigator:** The Principal Investigator is the applicant.

**Institutional Signing Official (ISO):** The ISO is the institutional representative responsible for signing and agreeing to the accuracy of the application and the terms and conditions of the award, should the application be selected for funding.

**Financial Officer:** The Financial Officer is the institutional representative responsible for the financial administration of externally funded research.

**Additional Access (Admin/Assistant):** Access may be given to personnel to assist in the application process. This is the institutional representative responsible for the day-to-day administration of externally funded research (or the Research Administrator).

**Technology/Transfer Official (TTO):** The TTO is the institutional representative responsible for overseeing Intellectual Property.

**Zip Code of the Institution:** Enter the zip code of the institution if located within the United States. You will need to click on the zip code from the drop-down menu to ensure it is captured in the zip code field. If not located within the US, this can be left blank.

**Co-PI:** You are allowed to have one Co-PI on your application. Please indicate their name, institution, and title. The designated Co-PI cannot be changed, or a new Co-PI cannot be added after submitting the Letter of Intent.
Project Information

Project Title: Provide a title adhering to the 100-character limitation (which includes spaces).

Project Summary: Provide a short summary (approximately 2-4 sentences) in lay language. Charts and graphs cannot be included in the project summary section of the LLS Research Portal.

Scientific Abstract: Briefly describe the proposed research in 3,000 characters (including spaces) or less using technical language. Once the LOI has been submitted, the scientific abstract may not change. Greek characters or symbols must not be used.

Brief Biography (for the PI only): Provide a brief, professional biography introducing the applicant to a lay audience. Approximately 1,000 characters including spaces.

Lay Description: The Lay Description should clearly state the relevance of your research to blood cancer and describe your current/proposed research, including the problem/question to be addressed, specific aims, and anticipated results using non-technical language that is easily understood by the lay community. Scientific/Greek characters or symbols must not be used. The Lay Description is essential for LLS to continue successful fundraising to support our current and future grantees, including the later years of your award, should it be funded. Thus, we require a well-written Lay Description, with sufficient detail and suitable language for non-scientists. Be aware of your confidential information, as the Lay Description (and Project Summary) will be shared with others. The Lay Description has a maximum of 3,000 characters, including spaces.

Amount Requested: The total amount, including both direct and indirect costs, cannot exceed $250,000/year. Enter the total amount of funding requested over the life of the grant (Maximum $750,000 for the life of the grant). The amount requested on the LLS Research Portal should match the budget section of the full application template. Please note that LLS does not follow NIH guidelines for budgets. Please adhere to the LLS rules as outlined in this document.

Proposed Start Date: The start date for TRP grants is July 1, 2024.

Proposed End Date: The end date for TRP grants is June 30, 2027.

Previous Submission: Indicate whether you have previously submitted this proposal (or one similar) to LLS and indicate the date of any prior submission.

Key Personnel or Collaborators Information: Include collaborators or key personnel (internal or external to your institution) that will help strengthen your application. Please include their name(s) and institution(s). This section helps LLS identify conflicts with reviewer assignments.

Previous Studies/Preliminary Data: Upload the Previous Studies/Preliminary Data template (1 page maximum) to the “Project and Supporting Documentation” section of the web form in PDF format. Text, figures, and references must be written single spaced in Arial size 11 font.

Note: When uploading this template to Fluxx, please ensure you choose the correct file name from the drop-down menu which should read “Previous Studies/Preliminary Data.” If the wrong file name is chosen, you will not be able to submit your LOI.

References are not required at the LOI phase, but you may provide them if you would like provided you adhere to the one-page limit.
LOI Save, Review, and Submit Instructions

Validation will automatically occur after clicking the “Save” button. Validation is a safety measure for the applicant to ensure that all required fields are complete. If required fields are empty or incomplete, the system notifies the applicant of fields that require information.

After clicking “Save” you will be directed to review your LOI. Please ensure all information is accurate, and then click the “Submit” button to submit your LOI to LLS.

Each applicant must submit the LOI by October 20, 2023, at 3:00 pm ET via the LLS Research Portal. After clicking the “Submit” button, the applicant will receive an automated email within 2 business days stating that your information was successfully submitted. If you do not receive the email confirmation within two business days, contact researchprograms@lls.org.

Signatures of the applicant and institution officials are not required for submission of the LOI.

Changes
Information collected in the Letter of Intent Phase will automatically populate fields in the full application. Once submitted, changes may only be made after receiving prior approval from LLS.

The applicant must email researchprograms@lls.org requesting any change and identifying the elements to be changed. Any changes made without the prior approval of LLS may result in the disqualification of the application.

Detailed Full Application Phase Instructions

Each applicant must submit a full application by January 19, 2024, at 3:00 pm ET via the LLS Research Portal. Some sections of the full application will be automatically captured on the LLS Research Portal from the Letter of Intent Phase. Other pieces of information will be captured in the application template that must be downloaded, completed, and then uploaded by the applicant as a single PDF. The applicant may not modify any information from the submitted Letter of Intent Phase as this is subject to the “Changes” section listed above and may result in disqualification of the application.

Failure to submit as a single PDF in the order below may result in disqualification of the application.

Three sections are required in the uploaded PDF:

Section 1: Graphical Abstracts (1 page maximum)
You will provide one or two graphical abstracts (which may also include text) to describe some aspects of your research, such as signaling pathways, overall approach, etc. These provide reviewers with quick overviews of your research. These are similar to what is seen at the beginning of a Cancer Cell paper, though they must not be professionally developed. They must be developed primarily by the applicant using tools readily available (e.g., PowerPoint, Photoshop, Adobe Illustrator, BioRender, etc.). You will be judged on your ability to convey information in a simple manner, but you will not be judged on artistic ability.
Section 2: Project Description (11 page maximum, including figures, 9 page maximum if no Patient Involvement Plan is required)

Download and complete the project description template, including all required signatures, and upload to the “Project or Supporting Documentation” section of the web form. Margins are preset and must not be changed. Text, figures, and references must be written single spaced in Arial size 11 font. Only one application PDF is accepted at the full application phase (Project Description Template combined with biosketch(es).

Do not delete the LOI “Previous Studies/Preliminary Data” PDF file.

The template consists of the following required elements:

a. Project Description (11 page maximum, including figures, 9 page maximum if no Patient Involvement Plan is required)

The following information should be provided in this order. The approximate length listed for each section in the sequence is a recommendation and not a strict limit for each section. It is up to the applicant to utilize more or less space for individual parts based off the specifics of their application.

- Title and Specific Aim (approximately 0.25 pages)
- Scientific and Clinical Significance of the Work (approximately 2.0 page)
- Previous Studies/Preliminary Data (approximately 3.0 pages)
- Research Methods (approximately 1.25 pages)
- Patient Involvement Plan Questions (approximately 2.0 pages)
- Interaction with Other Investigators (approximately 0.5 pages)
- Resources and Environment (major lab items or facilities) (approximately 1.0 page)
- References Cited (approximately 1.0 page)

Use Arial 11pt font for text, figures, and references.

b. Description of Model Systems and Reagents

Provide information on the models, drugs, and reagents described in your project description. This will be an easily assessable resource for reviewers to understand what is described in more detail in the text and figures.

c. Budget

The Budget and Budget Justification should provide itemized detail for each major category for all years of the project. The budget can be summarized in year one and extrapolated for the remaining two years. All totals and subtotals should be completed on the form.

The aggregate costs over three (3) years cannot exceed $750,000. The maximum annual total cost cannot exceed $250,000.

Permissible Direct Costs include the following with the specified limitations:

- Personnel Expenses including salary, wage, or stipend with fringe benefits.

  • In total, no more than forty percent (40%) of the direct costs may be requested for the salary and fringe benefit expenses of professional staff with a post-graduate degree (i.e. MD, PhD, DVM) regardless of function or role. This restriction does not apply to technical staff (lab
assistants, nurses, etc.).

- Supplies & Materials requests should be itemized by category.
- Equipment Purchase requests must identify each item of equipment with an acquisition cost of more than $4,000.
- Travel Expense requests cannot exceed $2,000 per year of the award.
- Patient Care Costs (Inpatient/Outpatient)
- Subcontract Costs
- Other Direct Cost requests

**Permissible Indirect Costs** (often referred to as Institutional Overhead, IDC, M&A, G&A, or pooled costs) are those costs incurred for common or joint objectives that cannot be readily identified with a particular project (general maintenance, utilities, library, etc.) as defined in the Office of Management and Budget, Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards. **Indirect costs are limited to 10% of the total award value of $750,000, or $250,000 per year.** For institutions that do not choose to use these funds for indirect costs, LLS allows the funds to be applied to the direct costs.

**Impermissible Costs** include membership dues, tuition, books, journals, and publication costs.

d. Budget Justification
   2 page maximum.

e. Signature Page
   This form must be completed, including the indicated signatures.

**Section 3: Appendix**
The following sections must be attached in this order to the end of the project description template (from Section 2) to create a single PDF. **No other information may be provided in this section.**

a. Principal Investigator’s NIH Biosketch (This document is not required for Senior Staff/Collaborators but is required for the Co-Principal Investigator)
   Use the most recent NIH biosketch format found on the NIH website. Publications submitted and under review should be indicated on the biosketch. An eRA Commons Username is not required.

b. Principal Investigator’s NIH Other Support Document (This document is not required for Senior Staff/Collaborators but is required for the Co-Principal Investigator)
   Use the most recent NIH Other Support Document format found on the NIH website. Must contain all current and pending support from any source. **In addition, specific aims must be listed for current and pending grants that may overlap or appear to overlap with the LLS application.** This includes any grants or portions of grants submitted to any organization, including LLS.

   If funding decisions about potentially overlapping, pending grants become available following submission of an LLS application, LLS must be notified within (5) five business days of the applicant’s receipt of that information.

   LLS recognizes that some investigations, particularly those involving clinical trials, may require multiple funding sources, so overlap of specific aims with another grant may be appropriate and acceptable. The need for and details about such overlap should be clearly explained in the application. However, LLS will consider an applicant’s other current grant
support in its funding decisions. This may result in LLS funding only part of the grant or none of the grant, depending on the level of overlap. In addition, LLS reserves the right to adjust the level of funding of an awarded grant should another overlapping or potentially overlapping grant that was pending at the time of grant submission be awarded to the applicant.

Failure to abide by LLS’s rules on disclosure of current or pending support may jeopardize the funding of the current grant application and may affect future LLS funding decisions.

c. Co-Principal Investigator’s NIH Biosketch (if applicable)
Use the most recent NIH biosketch format found on the NIH website. Publications submitted and under review should be indicated on the biosketch. An eRA Commons Username is not required.

d. Co-Principal Investigator’s NIH Other Support Document (if applicable)
Use the most recent NIH Other Support Document format found on the NIH website. This form must contain all current and pending support from any source. In addition, specific aims must be listed for current and pending grants that may overlap or appear to overlap with the LLS application. This includes any grants or portions of grants submitted to any organization, including LLS.

e. Collaboration/Support Letters
Required if reagents critical for the research are to be obtained from non-commercial and/or commercial sources and are not currently available in your lab.

f. Assurances (Required where applicable)
Provide a one-page summary and a link to the clinicaltrials.gov website for any clinical protocol essential to the proposed research. Include IRB approval date, IRB compliance number, and effective dates of approval. Projects for which IRB approval is pending must be accompanied by a signed letter from the appropriate institutional official. The applicant should notify LLS of IRB approval prior to the grant review. Any application without these letters attached may not be reviewed.

The applicant must provide information if a trial is receiving funding from a sponsor, specifically, how much money is to be received and what the funds will be used for.

Full approval for all assurances that are necessary for the research must be obtained by the award start date.

Description of Assurances

**Human Subjects:** The applicant must indicate if human materials or subjects will be involved in the proposed research. The status (approved, pending, or exempt) of the Institutional Review Board (IRB or equivalent oversight entity) approval must be provided. The Human Subject Assurance Number (OHRP) must be included. If the research project has received IRB approval, the date must be provided, and documentation must be included in the single PDF of the application. The application may be submitted with IRB approval pending but an award will not be made without documented IRB approval if it was pending at the time of application submission. It is recommended that the applicant notify LLS before the grant review if the IRB status has changed. If a project is exempt from IRB review, the certificate of exemption must be included in the single PDF of the application.
**Laboratory Animals:** The applicant must indicate if laboratory animals will be involved in the proposed research. The status and date of Institutional Animal Care and Use Committee (IACUC or equivalent oversight entity) approval must be provided. The Animal Welfare Assurance number must be included. Documentation of institutional approval must be included in the single PDF of the application. The application may be submitted with IACUC approval pending but an award will not be made without documented IACUC approval if it was pending at the time of application submission. It is recommended that the applicant notify LLS before the grant review if the IACUC status has changed.

**Recombinant DNA:** The applicant must indicate if the proposed research involves the use of recombinant DNA. Documentation of institutional approval must be included in the single PDF of the application.

**Biohazard Statement:** The applicant must indicate if the proposed research involves the use of biohazards. If the applicant indicates affirmatively, then an institutional statement of assurances regarding potential biohazards and safeguards must be included in the single PDF of the application.

Note: Your institution is required to have assurance procedures in place, so please check with them if you are unsure how to obtain your assurance approval documentation.

*No attachments besides those listed above can be included in the Appendix. Applications that include additional documents besides those requested may be administratively disqualified.*

**Uploading the project document and final submission**
All final application documents must be combined into a single PDF in the order listed above. Failure to submit as a single PDF in the order above may result in disqualification of the application. Upload the full application components, as a single PDF, in the “Project and Supporting Documentation” section on the web form. The file upload should be labeled, “TRP Project Description/Application” which you can choose from the document upload drop-down menu. **Do not delete the LOI “Previous Studies/Preliminary Data” PDF file.**

**Fluxx Webform Updates**
- **Budgeting Information**
  Enter the budgeting information as required on the web form fields.

- **Applicant Assurance**
  Check the box to accept the terms as stated on the web form field.

**Save and Review**
Validation will automatically occur after clicking the “Save” button. Validation is a safety measure for the applicant to ensure that all required fields are complete. If required fields are empty or incomplete, the system notifies the applicant of fields that require information.

**Submission & Confirmation**
After clicking the “Submit” button, you will receive an automated email **within 2 business days** stating that your information was successfully submitted. **If you do not receive the email**
confirmation of submission, contact LLS at researchprograms@lls.org.

Only one application document and one Letter of Intent request document should be present. If extra documents remain after submission and before the deadline, email researchprograms@lls.org and let us know which documents to remove.

Carefully check your PDF prior to submission. If you notice problems with your PDF after you have submitted, email researchprograms@lls.org, and we will help you upload the correct document if you are unable to delete the incorrect document. This email must be received, with the correct document, prior to the deadline; there are no exceptions to this rule.

The applicant is ultimately responsible for the submission, regardless of who actually is uploading information on the LLS Research Portal. Every year, LLS has a small number of people that notice problems with their application after the deadline. The solution to this problem is very simple and in the hands of the applicant:

- Check your application prior to final submission.
- Submit well ahead of the deadline.
- We are not responsible if any applicants are unable to submit by the deadline if our system indicates that:
  a. the application procedure was started less than 24 hours before the deadline, or
  b. a previously started application file was then only picked up again less than 3 hours before the deadline

Once the deadline has passed, only the following updates may be made:

- Regulatory approvals
- Significant updates to clinical trials:
  o IRB updates
  o Opening of the trial
  o Patient enrollment
  o Opening of new clinical sites
  o Efficacy and/or safety updates
- Updates regarding any transfers to a new institution

If you plan to withdraw your application at any time during the application cycle, please inform LLS staff of your decision by writing to researchprograms@lls.org.
The Follicular Lymphoma Foundation (FLF) was established in 2019 as an international effort on a mission to identify new treatments and cures for follicular lymphoma (FL).

The Follicular Lymphoma Foundation and LLS are partnering to seek research projects to accelerate the development of therapeutic candidates with the potential to cure FL at first relapse, either as monotherapy or in a combination approach.

Through The LLS-FLF United to CURE FL Award, FLF and LLS intend to award up to three research grants, each providing funding as outlined in the LLS TRP (up to $750,000 over 3 years). These grants would support research projects focused on FL, led by Ph.D. level and/or M.D. level investigators.

FLF and LLS encourage investigators with promising ideas to apply, regardless of prior research experience specifically in FL.

**Background:**

While outcomes for patients with FL have improved substantially over the last 40 years, there remains a very high level of unmet need in the FL Patient population. Nearly all patients will experience relapse and often multiple relapses, over the course of their disease. A subset of patients experience early disease progression or transformation to aggressive disease, with 5-year survival rates as low as 50%. Even patients with more favorable survival rates endure significant challenges - the psychological toll of an incurable, relapsing disease, increasing toxicities of therapies designated for later relapses, and ongoing risk of transformation to aggressive lymphoma.

FL has rarely been the central focus for drug development: historically, most drugs available to treat FL were first evaluated for other lymphomas. Putting FL front and center will catalyze focused development of therapies for this underserved patient population.

Ultimately, the goal is to make curative therapies available to FL patients as soon as possible.

**Scientific Focus:**

Proposals shall focus on accelerating the development of immune system engaging therapies, including cellular (e.g., CAR-T) and humoral (e.g., bispecific molecules) approaches, and/or targeted therapy for FL.

In the long term, rational sequencing of these two classes is likely to be curative in a larger fraction of patients than either single approach. However, combination therapy for FL may not be an appropriate pursuit until more is known about optimal patient selection, mechanisms of resistance, and duration of effect of each distinct class.
As such, programs that advance each therapeutic strategy separately with line of sight to a future combination approach may offer the greatest value to patients in both the near and long term.

1. **Immunotherapy:**

   Immunotherapy is very effective against FL in terms of high response rates and durability. Although such therapies are believed to hold great promise for a curative effect, no plateau in relapse-free survival curves is yet apparent.

   1.1. **Cellular immunotherapy: CAR-T, and others.**

       Anti-CD19 targeted CAR-T has demonstrated efficacy against relapsed or refractory (r/r) FL. As an example, a 95% overall response rate and 81% complete response in r/r FL patients treated with axi-cel (Yescarta®, ZUMA-5 study), and with limited but compelling follow up data show many maintaining that response in this study and others. The FDA has approved 4 CAR-T therapies; three of the four are indicated or in NDA for r/r or transformed FL. New CAR technologies are advancing this modality, including the optimization of costimulatory and other CAR domains. However, CAR-T therapies are limited by many factors, such as a small menu of known tumor antigens presented on the cell surface, T cell exhaustion, etc., and others as yet unknown.

       For cell therapy, better ways to engineer, grow and target T cells will improve safety, long term efficacy and accessibility. Other immune cells such as NK cells may play a therapeutic role. A more detailed understanding of the host immune system in patients with FL and their lymphoma microenvironment would enhance the development and use of immunotherapies.

   1.2. **Bi-specific T cell engagers (bispecific antibodies and related constructs):**

       Bispecific antibodies and related constructs targeting CD20 on B cells and CD3 on T cells are active in patients with r/r FL, with mosunetuzumab FDA approved in later lines of therapy, and other agents in late-stage development, either alone or in combination in earlier lines of therapy. Permutations with different structures, different B and T cell targets, additional co-stimulatory targets, etc. are under active investigation. Optimization of many factors regarding BITES could advance outcomes of patients with FL.

       As for cellular immunotherapy, understanding and modifying the host immune response and microenvironment are likely to improve outcomes with these agents as well.

2. **Targeted therapy:** epigenetic regulators, and others.

   Accumulating data indicates the important roles of epigenetic mutations commonly found in FL. Tazemetostat, FDA approved in 2020 for r/r FL, has shown a 68-82% overall response rate in r/r FL patients with an EZH2 mutation, a lower response rate for wild-type EZH2, but relatively short durations in both groups. HDAC inhibitors have induced overall response rates of 47% - 64%. However, complete response rates and response durations have been low in both classes, and expansion of the epigenetic toolkit has been hampered in part by the difficulty in targeting loss of function mutations. Proposed research investigating targeted therapy is not limited to epigenetic regulators, and other classes of targeted therapies may be proposed if supported by strong biological rationale.
While targeted drugs administered as monotherapies are less likely to achieve curative impact, they still can play an important role in the FL armament. Given the high frequency of FL epimutations, and evidence for their role in tumor evasion of immune surveillance, epigenetic reprogramming could potentially prime, amplify or sustain an immunotherapeutic effect. This class may also be capable of targeting the underlying common precursor cell population.

Key considerations for proposals:

- Projects may be preclinical, IND-enabling, or Phase I or I/II.
- Any biologically validated target(s) or novel cell or antibody-based engineering process may be proposed. Regarding targeted therapy development, there is particular interest in epigenetic mechanisms.
- Designs that explore and exploit resistance pathways, e.g., antigen escape, T cell exhaustion, etc. to current or novel approaches are encouraged.
- Given high industry activity in this space, proposals must articulate how and why philanthropic funding will accelerate the timeline of impactful therapeutic development.

Note that FLF finds it an acceptable strategy to leverage awarded funding in conjunction with additional funding entities, opportunities, or partnerships to achieve described outcomes. Should an applicant choose to pursue an alternative funding pathway, it should be clearly described within the proposed research plan.

Alongside the scientific peer review panel, all applications will be subject to a Patient Review panel. Patients will review the lay summary and description. The potential clinical impact and timeframe of such impact is often of interest to the Patient Review panel.

Please ensure applications include aims with clear milestones (at six-month intervals, starting at month six), extending through the full proposed timeframe.